Free shipping on orders over $99
Advances in Multiple Sclerosis and Experimental Demyelinating Diseases

Advances in Multiple Sclerosis and Experimental Demyelinating Diseases

by Moses Rodriguez
Hardback
Publication Date: 05/12/2007

Share This Book:

  $249.00
or 4 easy payments of $62.25 with
afterpay
This item qualifies your order for FREE DELIVERY
Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people in the United States. With their novel, multifaceted approach to basic science, the authors of this book offer help to clinicians and hope to patients.
ISBN:
9783540736769
9783540736769
Category:
Immunology
Format:
Hardback
Publication Date:
05-12-2007
Language:
English
Publisher:
Springer-Verlag Berlin and Heidelberg GmbH & Co. KG
Country of origin:
Germany
Pages:
362
Dimensions (mm):
235x155x25mm
Weight:
0.74kg

This title is in stock with our Australian supplier and should arrive at our Sydney warehouse within 2 - 3 weeks of you placing an order.

Once received into our warehouse we will despatch it to you with a Shipping Notification which includes online tracking.

Please check the estimated delivery times below for your region, for after your order is despatched from our warehouse:

ACT Metro: 2 working days
NSW Metro: 2 working days
NSW Rural: 2-3 working days
NSW Remote: 2-5 working days
NT Metro: 3-6 working days
NT Remote: 4-10 working days
QLD Metro: 2-4 working days
QLD Rural: 2-5 working days
QLD Remote: 2-7 working days
SA Metro: 2-5 working days
SA Rural: 3-6 working days
SA Remote: 3-7 working days
TAS Metro: 3-6 working days
TAS Rural: 3-6 working days
VIC Metro: 2-3 working days
VIC Rural: 2-4 working days
VIC Remote: 2-5 working days
WA Metro: 3-6 working days
WA Rural: 4-8 working days
WA Remote: 4-12 working days

Reviews

Be the first to review Advances in Multiple Sclerosis and Experimental Demyelinating Diseases.